Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men.
The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Abstract
Organs that respond to and metabolize GH are enriched in cognate high-affinity receptors. However, whether isologous receptors mediate the de facto access of ligand to cellular degradative pathways is not known. To address this query, we assessed the distribution and whole-body elimination kinetics of (endogenous and exogenous) GH before and after administration of a novel, potent, and selective recombinant human (rh) GH receptor antagonist peptide, pegvisomant. Sixteen healthy young adults (nine men and seven women) participated in a double-blind, prospectively randomized, within-subject cross-over study. The intervention comprised a single sc injection of placebo vs. a high dose of pegvisomant (1 mg/kg sc) timed 62 and 74 h before the overnight sampling and daytime infusion sessions, respectively. The half-life, metabolic clearance rate (MCR), and distribution volume of GH were quantitated by way of: 1) deconvolution analysis of serum GH concentration time series collected every 10 min for 10 h; 2) exponential regression analysis of the decay of GH concentrations after a 6-min iv pulse of rhGH (1 and 10 μg/kg); 3) calculation of the MCR during constant iv infusion of rhGH (0.5 and 5.0 μg/kg every 2 h); and 4) exponential fitting of the elimination time-course of GH concentrations following cessation of each constant infusion. Concentrations of GH and pegvisomant were measured in separate, noncross-reactive, two-site monoclonal, immunofluorometric assays. Pegvisomant concentrations averaged 4860 ± 480 μg/liter (±sem) across the infusion interval, thus exceeding low steady state GH concentrations by 3000-fold. Inhibitory efficacy of the GH receptor antagonist peptide was affirmed by way of a 34% reduction in the serum total IGF-I concentration, i.e., from 257 ± 37 (placebo) to 170 ± 24 (drug) μg/liter (P < 0.001); and a reciprocal 77% elevation of the (10-h) mean GH concentration, i.e., from 1.3 ± 0.23 (placebo) to 2.3 ± 0.42 (drug) μg/liter (P = 0.003). ANOVA disclosed that prior administration of pegvisomant (compared with placebo) did not alter: 1) the calculated half-life (minutes) of secreted GH, which averaged 15 ± 1.3 (placebo) and 14 ± 0.69 (drug); 2) the half-time of disappearance (minutes) of an iv pulse of rhGH, 15 ± 1.0 (placebo) and 13 ± 0.5 (drug) (for the 10 μg/kg dose); 3) the distribution volume (milliliters per kilogram) of rhGH, 59 ± 6.2 (placebo) and 58 ± 3.5 (drug); 4) the steady state GH concentration (micrograms per liter) attained during constant iv infusion of rhGH (at a rate of 5 μg/kg every 2 h), 18.2 ± 2.4 (placebo) and 18.3 ± 2.3 (drug); 5) the half-life (minutes) of elimination of GH from equilibrium, 16 ± 0.98 (placebo) and 16 ± 1.8 (drug); and 6) the steady state MCR (liters per kilogram per day) of rhGH, 3.8 ± 0.32 (placebo) and 3.5 ± 0.31 (drug). In ensemble, the present data refute the a priori postulate that vascular-accessible GH receptors determine the in vivo pseudoequilibrium kinetics of GH disappearance in the human.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“infusion of IGF-I suppresses and experimental reduction of IGF-I concentrations stimulates pulsatile GH secretion by approximately 2-fold (26,27).”
From Determinants of dual secretagogue drive of burst-like growth hormone secretion in premenopausal women studied under a selective estradiol clamp (2005) · cites this paper as [26]
Citations
Cites
Human Growth Hormone and Extracellular Domain of Its Receptor: Crystal Structure of the Complex
de Vos, A. M., Ultsch, M., & Kossiakoff, A. A. (1992) · Science · doi:10.1126/science.1549776 · Cited by 2,239
Growth hormone receptor and serum binding protein: purification, cloning and expression
Leung, D. W., Spencer, S. A., Cachianes, G., Hammonds, R. G., Collins, C., Henzel, W. J., Barnard, R., Waters, M. J., & Wood, W. I. (1987) · Nature · doi:10.1038/330537a0 · Cited by 1,522
Giustina, A., & Veldhuis, J. D. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.6.0353 · Cited by 1,253
Self-citationTreatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant
Trainer, P. J., Drake, W. M., Katznelson, L., Freda, P. U., Herman-Bonert, V., van der Lely, A. J., Dimaraki, E. V., Stewart, P. M., Friend, K. E., Vance, M. L., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004203421604 · Cited by 879
Self-citationCunningham, B. C., Ultsch, M., de Vos, A. M., Mulkerrin, M. G., Clauser, K. R., & Wells, J. A. (1991) · Science · doi:10.1126/science.1948064 · Cited by 874
Zhou, Y., Xu, B. C., Maheshwari, H. G., He, L., Reed, M., Lozykowski, M., Okada, S., Cataldo, L., Coschigamo, K., Wagner, T. E., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13215 · Cited by 802
Rational Design of Potent Antagonists to the Human Growth Hormone Receptor
Fuh, G., Cunningham, B. C., Fukunaga, R., Nagata, S., Goeddel, D. V., & Wells, J. A. (1992) · Science · doi:10.1126/science.256.5064.1677 · Cited by 631
Veldhuis, J. D., Carlson, M. L., & Johnson, M. L. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7686 · Cited by 549
Self-citationGrowth Hormone Heterogeneity: Genes, Isohormones, Variants, and Binding Proteins
BAUMANN, G. (1991) · Endocrine Reviews · doi:10.1210/edrv-12-4-424 · Cited by 443
Essential Role of Growth Hormone in Ischemia-Induced Retinal Neovascularization
Smith, L. E. H., Kopchick, J. J., Chen, W., Knapp, J., Kinose, F., Daley, D., Foley, E., Smith, R. G., & Schaeffer, J. M. (1997) · Science · doi:10.1126/science.276.5319.1706 · Cited by 393
Research works printed but not linked: 1
- Guyton, 2000, The body fluid compartments: extracellular and intracellular fluids; interstitial fluid and edema, In: Textbook of medical physiology, vol 10. Philadelphia: WB Saunders Co.;, 264
Cited by
Endocrine Control of Body Composition in Infancy, Childhood, and Puberty
Veldhuis, J. D., Roemmich, J. N., Richmond, E. J., Rogol, A. D., Lovejoy, J. C., Sheffield-Moore, M., Mauras, N., & Bowers, C. Y. (2005) · Endocrine Reviews · doi:10.1210/er.2003-0038 · Cited by 452
Self-citationSomatotropic and Gonadotropic Axes Linkages in Infancy, Childhood, and the Puberty-Adult Transition
Veldhuis, J. D., Roemmich, J. N., Richmond, E. J., & Bowers, C. Y. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0006 · Cited by 236
Self-citationHigh-Sensitivity Chemiluminescence Immunoassays for Detection of Growth Hormone Doping in Sports
Bidlingmaier, M., Suhr, J., Ernst, A. S., Wu, Z., Keller, A., Strasburger, C. J., & Bergmann, A. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.112458 · Cited by 155
Self-citationKopchick, J. J., List, E. O., Kelder, B., Sustarsic, E. G., & Berryman, D. E. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.09.004 · Cited by 100
Growth Hormone Receptor Antagonists
Muller, A. F., Kopchick, J. J., Flyvbjerg, A., & van der Lely, A. J. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-022049 · Cited by 90
Treatment of Acromegaly with Pegvisomant during Pregnancy: Maternal and Fetal Effects
Brian, S. R., Bidlingmaier, M., Wajnrajch, M. P., WEINZIMER, S. A., & Inzucchi, S. E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0997 · Cited by 95
Self-citationHuman GH pulsatility: An ensemble property regulated by age and gender
Veldhuis, P. P., & Bowers, C. Y. (2003) · Journal of Endocrinological Investigation · doi:10.1007/bf03345229 · Cited by 92
Automated 22-kD Growth Hormone–Specific Assay without Interference from Pegvisomant
Manolopoulou, J., Alami, Y., Petersenn, S., Schopohl, J., Wu, Z., Strasburger, C. J., & Bidlingmaier, M. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2012.188128 · Cited by 75
Self-citationBuchfelder, M., Weigel, D., Droste, M., Mann, K., Saller, B., Brübach, K., Stalla, G. K., Bidlingmaier, M., Strasburger, C. J., & _, _. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-0910 · Cited by 79
Self-citationAspects of placental growth hormone physiology
Fuglsang, J., & Ovesen, P. (2006) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2006.03.010 · Cited by 71
The German ACROSTUDY: past and present
Buchfelder, M., Schlaffer, S.-M., Droste, M., Mann, K., Saller, B., Brübach, K., Stalla, G. K., Strasburger, C. J., & _, _. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0350 · Cited by 71
Self-citationSomatotroph Tumor Progression during Pegvisomant Therapy: A Clinical and Molecular Study
Marazuela, M., Paniagua, A.-E., Gahete, M. D., Lucas, T., Alvarez-Escolá, C., Manzanares, R. G., Cameselle‐Teijeiro, J., Luque‐Ramírez, M., Luque, R. M., Fernandez-Rodriguez, E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1742 · Cited by 70
Yin, D., Vreeland, F., Schaaf, L. J., Millham, R., Duncan, B. A., & Sharma, A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1910 · Cited by 68
PEGylation of somatropin (recombinant human growth hormone): Impact on its clearance in humans
Webster, R., Xie, R., Didier, E., Finn, R. F., Finnessy, J., Edgington, A., & Walker, D. K. (2008) · Xenobiotica · doi:10.1080/00498250802413856 · Cited by 67
Marazuela, M., Lúcas, T., Álvarez‐Escolá, C., Puig‐Domingo, M., de la Torre, N. G., de Miguel-Novoa, P., Duran-Hervada, A., Manzanares, R. G., Luque‐Ramírez, M., Halperín, I., et al. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-0705 · Cited by 65
A ligand-receptor fusion of growth hormone forms a dimer and is a potent long-acting agonist
Wilkinson, I., Ferrandis, E., Artymiuk, P. J., Teillot, M., Soulard, C., Touvay, C., Pradhananga, S. L., Justice, S., Wu, Z., Leung, K. C., et al. (2007) · Nature Medicine · doi:10.1038/nm1610 · Cited by 45
Self-citationEstrogen Elevates the Peak Overnight Production Rate of Acylated Ghrelin
Paulo, R., Brundage, R. C., Cosma, M., Mielke, K. L., Bowers, C. Y., & Veldhuis, J. D. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0783 · Cited by 42
Self-citationModel-projected mechanistic bases for sex differences in growth hormone regulation in humans
Farhy, L. S., Bowers, C. Y., & Veldhuis, J. D. (2006) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00584.2006 · Cited by 41
Self-citationTechnology Insight: detecting growth hormone abuse in athletes
Bidlingmaier, M., & Strasburger, C. J. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0644 · Cited by 34
Self-citationVeldhuis, J. D., & Bowers, C. Y. (2003) · Endocrine · doi:10.1385/endo:22:1:25 · Cited by 32
Self-citationPegvisomant, a Growth Hormone-Specific Antagonist, Undergoes Cellular Internalization
Maamra, M., Kopchick, J. J., Strasburger, C. J., & Ross, R. J. M. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031781 · Cited by 29
Self-citationPharmacological Therapy for Acromegaly: A Critical Review
Muller, A. F., & van der Lely, A. J. (2004) · Drugs · doi:10.2165/00003495-200464160-00007 · Cited by 29
Veldhuis, J. D., Patrie, J. T., Frick, K., Weltman, J. Y., & WELTMAN, A. L. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0430 · Cited by 27
Self-citationErickson, D., Keenan, D. M., Mielke, K., Bradford, K., Bowers, C. Y., Miles, J. M., & Veldhuis, J. D. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0424 · Cited by 26
Self-citationSerum IGF-I Is Not a Reliable Pharmacodynamic Marker of Exogenous Growth Hormone Activity in Mice
Bielohuby, M., Schaab, M., Kummann, M., Sawitzky, M., Gebhardt, R., Binder, G., Frystyk, J., Bjerre, M., Hoeflich, A., Kratzsch, J., et al. (2011) · Endocrinology · doi:10.1210/en.2011-1432 · Cited by 25
Self-citationA Tripeptidyl Ensemble Perspective of Interactive Control of Growth Hormone Secretion
Veldhuis, J. D. (2003) · Hormone Research in Paediatrics · doi:10.1159/000071232 · Cited by 25
Self-citationTamshen, K., Wang, Y., Jamieson, S. M. F., Perry, J. K., & Maynard, H. D. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00365 · Cited by 23
Erickson, D., Keenan, D. M., Farhy, L., Mielke, K., Bowers, C. Y., & Veldhuis, J. D. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1621 · Cited by 21
Self-citationDetermination of Free Growth Hormone
Frystyk, J., Andreasen, C. M., & Fisker, S. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0375 · Cited by 21
Bielohuby, M., Zarkesh‐Esfahani, S. H., Manolopoulou, J., Wirthgen, E., Walpurgis, K., Khorasgani, M. T., Aghili, Z. S., Wilkinson, I., Hoeflich, A., Thevis, M., et al. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.016519 · Cited by 21
Self-citationA Pegylated Growth Hormone Receptor Antagonist, Pegvisomant, Does Not Enter the Brain in Humans
Veldhuis, J. D., Bidlingmaier, M., Bailey, J. N., Erickson, D. Z., & Sandroni, P. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0538 · Cited by 21
Self-citationWu, L., Ho, S. V., Wang, W., Gao, J., Zhang, G., Su, Z. G., & Hu, T. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.06.022 · Cited by 17
Wang, Y., Langley, R. J., Tamshen, K., Jamieson, S. M. F., Lu, M., Maynard, H. D., & Perry, J. K. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00208 · Cited by 15
Enhanced Bioactivity of a Human GHR Antagonist Generated by Solid-Phase Site-Specific PEGylation
Wang, Y., Langley, R. J., Tamshen, K., Harms, J. K., Middleditch, M., Maynard, H. D., Jamieson, S. M. F., & Perry, J. K. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.0c01105 · Cited by 15
Roemmler, J., Steffin, B., Gutt, B., Schneider, H. J., Sievers, C., Bidlingmaier, M., & Schopohl, J. (2010) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2010.05.004 · Cited by 15
Self-citationRoelfsema, F., Yang, R. J., Takahashi, P. Y., Erickson, D. Z., Bowers, C. Y., & Veldhuis, J. D. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2017-00457 · Cited by 13
Self-citationOjima, D., & Iwata, M. (2007) · Aquaculture · doi:10.1016/j.aquaculture.2007.10.014 · Cited by 13
Kinetics and secretion of placental growth hormone around parturition
Fuglsang, J., Sandager, P., Møller, N., Fisker, S., Ørskov, H., & Ovesen, P. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02109 · Cited by 13
Detecting Growth Hormone Abuse in Athletes
Bidlingmaier, M., & Manolopoulou, J. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2009.10.006 · Cited by 13
Self-citationMedical treatment in acromegaly
Paisley, A. N., & Trainer, P. J. (2003) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2003.07.007 · Cited by 13
Klitgaard, T., Nielsen, J. N., Skettrup, M. P., Harper, A., & Lange, M. (2009) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2009.02.004 · Cited by 12
Clinical Use of Pegvisomant for the Treatment of Acromegaly
Drake, W. M., & Trainer, P. J. (2003) · Treatments in Endocrinology · doi:10.2165/00024677-200302060-00001 · Cited by 11
Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomant
Drake, W. M., Berney, D. M., Kovács, K., & Monson, J. P. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01961 · Cited by 11
Growth hormone receptor antagonists.
Kohn, D. T., & Kopchick, J. (2002) · PubMed · Cited by 10
Muto, C., Chiba, K., & Suwa, T. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010386954 · Cited by 9
Pegvisomant: current and potential novel therapeutic applications
Thankamony, A., Dunger, D. B., & Acerini, C. L. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903449222 · Cited by 9
Diabetic retinopathy, nephropathy and cardiovascular disease in a patient with GH gene deletion
Laron, Z., & Weinberger, D. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02402.x · Cited by 8
Growth hormone distribution kinetics are markedly reduced in adults with growth hormone deficiency
Catalina, P. F., Páramo, C., Andrade, M. A., & Mallo, F. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02733.x · Cited by 8
Roemmler, J., Steffin, B., Gutt, B., Sievers, C., Bidlingmaier, M., & Schopohl, J. (2008) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2008.11.002 · Cited by 6
Self-citationPegvisomant‐primed GH stimulation test
Radetti, G., Wu, Z., Elsedfy, H. H., Kholy, M. E., Bozzola, M., & Strasburger, C. J. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03132.x · Cited by 5
Self-citationRak, A., & Gregoraszczuk, E. Ł. (2010) · Gynecological Endocrinology · doi:10.3109/09513591003592726 · Cited by 5
Yuen, K. C. J., Frystyk, J., Rhoads, S. A., & Bidlingmaier, M. (2015) · Pituitary · doi:10.1007/s11102-015-0688-8 · Cited by 4
Self-citationde Graaf‐Roelfsema, E., Veldhuis, P. P., van Dam, K. G., Menheere, P. P. C. A., KEIZER, H. A., Johnson, M. L., van Breda, E., Wijnberg, I. D., & van der Kolk, J. H. (2011) · Veterinary Quarterly · doi:10.1080/01652176.2011.571381 · Cited by 4
Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant
Drake, W. M., Loureiro, R. A., Parkinson, C., Monson, J. P., BESSER, G. M., & Trainer, P. J. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01822 · Cited by 4
Radetti, G., Elsedfy, H. H., Khalaf, R. I., Kholy, M. E., Meazza, C., Pagani, S., Bozzola, M., Albertini, R., Stefano, A. M. D., Navarra, A., et al. (2017) · HORMONES · doi:10.14310/horm.2002.1748 · Cited by 3
Sasaki, H., Ishibashi, A., Tsuchiya, Y., Shimura, N., Kurihara, T., Ebi, K., & Goto, K. (2015) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2015.07.005 · Cited by 3
Radetti, G., Elsedfy, H. H., Khalaf, R. I., Meazza, C., Pagani, S., Kholy, M. E., Albertini, R., Stefano, A. M. D., Navarra, A., SILVESTRI, A. D., et al. (2017) · HORMONES · doi:10.1007/bf03401523 · Cited by 3
Svensson, J., Johannsson, G., Iranmanesh, A., Albertsson-Wikland, K. G., Veldhuis, J. D., & Bengtsson, B. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02182 · Cited by 3
Self-citationBody Composition and Adipokine Levels in Growth Hormone Antagonist Mice
Magon, V. (2009) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 2
Stock, P., Bielohuby, M., Staege, M. S., Hsu, M., Bidlingmaier, M., & Christ, B. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.11.016 · Cited by 2
Self-citationDetecting growth hormone abuse in athletes
Strasburger, C. J., Bidlingmaier, M., & Wu, Z. (2005) · Endocrine Abstracts · Cited by 2
Self-citationGrowth Hormone and Translational Research: From the 'Bench' to the 'Bedside'
Kopchick, J. J., Berryman, D. E., Sustarsic, E. G., & List, E. O. (2011) · Endocrinology and Metabolism · doi:10.3803/enm.2011.26.4.285 · Cited by 1
Plazentares Wachstumshormon und seine Bedeutung bei Patientinnen mit Glukosestoffwechselstörungen
Friess, S. C. (2006) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.4971 · Cited by 1
New Insights into Medical Treatment of Acromegaly
Neggers, B. (2011) · RePub (Erasmus University Rotterdam)
Metadata
- Authors
- Veldhuis, J. D., Bidlingmaier, M., Anderson, S. M., Evans, W. S., Wu, Z., & Strasburger, C. J.
- Affiliations
- University of Virginia Health System (US)
- LMU Klinikum (DE)
- Corresponding author
- Veldhuis, J. D.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2002-12-01
- Volume
- 87
- Issue
- 12
- Pages
- 5737-5745
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2066506983
- Semantic Scholar
- 9bf65d066381e742648f04d341c370c70ba90520
- Cited by
- 61
- References
- 45
- Citations by year
- 2020: 3 · 2017: 4 · 2015: 2 · 2014: 1 · 2013: 2 · 2012: 1
- FWCI
- 3.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Virginia
- Deutsches Krebsforschungszentrum
- National Institutes of Health (RR-00847)
- National Institute on Aging (R01-AG14799-05, AG-19695-01, R01AG014799)
- National Center for Research Resources (M01RR000847, MO1-RR00847)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
- Keywords
- growth hormone, growth hormone receptor, pegvisomant, growth hormone receptor antagonist, metabolic clearance rate, volume of distribution, elimination half-life, insulin-like growth factor I, recombinant human growth hormone, healthy adults, sex differences, deconvolution, growth hormone binding protein
- MeSH terms
- Adult, Double-Blind Method, Female, Humans, Kinetics, Male, Prospective Studies, Receptors, Somatotropin, Recombinant Proteins, Reference Values, Cross-Over Studies, Human Growth Hormone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.